Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

IF 3.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
{"title":"Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus","authors":"","doi":"10.1002/adtp.202400330","DOIUrl":null,"url":null,"abstract":"<p><i>Adv. Therap. 2023, 2300143</i></p><p>Our NIH Program officer would like us to remove the funding association of grant R01DE31812 from the funding section of this PUBLISHED manuscript since it is not directly part of the Aims of the grant.</p><p>We apologize for this error.</p><p>In page 11, Acknowledgements section: “V.A.K. acknowledges support from the NIH NEI R15 EY029504, NIH NIDCR R01DE031812, NIH NIAMS R21AR079708, NIH NIAMS R01AR080895, NIH NIDCR R01DE029321, and NIH NCATS UL1TR003017, and the Undergraduate Research and Innovation program at NJIT” was incorrect. The text should read:</p><p>“V.A.K. acknowledges support from the NIH NEI R15 EY029504, NIH NIAMS R21AR079708, NIH NIAMS R01AR080895, NIH NIDCR R01DE029321, and NIH NCATS UL1TR003017, and the Undergraduate Research and Innovation program at NJIT”</p><p>We apologize for this error.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 9","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400330","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adtp.202400330","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Adv. Therap. 2023, 2300143

Our NIH Program officer would like us to remove the funding association of grant R01DE31812 from the funding section of this PUBLISHED manuscript since it is not directly part of the Aims of the grant.

We apologize for this error.

In page 11, Acknowledgements section: “V.A.K. acknowledges support from the NIH NEI R15 EY029504, NIH NIDCR R01DE031812, NIH NIAMS R21AR079708, NIH NIAMS R01AR080895, NIH NIDCR R01DE029321, and NIH NCATS UL1TR003017, and the Undergraduate Research and Innovation program at NJIT” was incorrect. The text should read:

“V.A.K. acknowledges support from the NIH NEI R15 EY029504, NIH NIAMS R21AR079708, NIH NIAMS R01AR080895, NIH NIDCR R01DE029321, and NIH NCATS UL1TR003017, and the Undergraduate Research and Innovation program at NJIT”

We apologize for this error.

比较 SGLT1、SGLT2 和双重抑制剂在治疗 2 型糖尿病中的生物活性
Adv.2023,2300143我们的 NIH 项目官员希望我们将 R01DE31812 号基金的资助协会从这篇已发表稿件的资助部分中删除,因为它不是基金目标的直接组成部分:第11页,致谢部分:"V.A.K.感谢美国国立卫生研究院NEI R15 EY029504、美国国立卫生研究院NIDCR R01DE031812、美国国立卫生研究院NIAMS R21AR079708、美国国立卫生研究院NIAMS R01AR080895、美国国立卫生研究院NIDCR R01DE029321、美国国立卫生研究院NCATS UL1TR003017以及新泽西理工学院本科生研究与创新项目的支持 "有误。文中应为:"V.A.K.感谢美国国立卫生研究院NEI R15 EY029504、美国国立卫生研究院NIAMS R21AR079708、美国国立卫生研究院NIAMS R01AR080895、美国国立卫生研究院NIDCR R01DE029321和美国国立卫生研究院NCATS UL1TR003017以及新泽西理工学院本科生研究与创新项目的支持"。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced Therapeutics
Advanced Therapeutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.10
自引率
2.20%
发文量
130
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信